REMSIMA

Subcutaneous biosimilar medications for patient self-administration

COMMERCIAL BRAND
REMSIMA

ACTIVE PRINCIPLE
INFLIXIMAB

TYPE OF DEVICE
PRE-FILLED PEN

LATEX
DO NOT

TEMPERING TIME
30 min

START OF INJECTION
Pressing against the skin

CLICK TO THE START (IN PEN)
DO NOT

CLICK AT THE END (IN PEN)
DO NOT

BioSim Newsletter

Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.

SUBSCRIBE